Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOVip
2023-504986-22-00Phase 3Authorised
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Aug 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in surgical site infection (SSI) comparing Linezolid prophylaxis with Vancomycin prophylaxis (2 arms). Primary endpoint: 30-day postoperative surgical site infection rate. Planned start Aug 2023; status: authorised.
02
Drugs
linezolidvancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on 2023-504986-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504986-22-00.